Kratom Research

Current sort has key articles at the top. Click on "Article Date" to sort by date, click on specific "tag" to view all articles in that category.

Title/Link
Kratom (Mitragynine) Toxicity: What Paramedics Need to Know
11/17/2026

The evidence is overwhelming, and the law is clear. Under 21 U.S.C. § 812(b)(1), a Schedule I placement requires demonstrating a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. The primary psychoactive alkaloids, mitragynine and 7-hydroxymitragyine act as partial and full agonists at the m-opioid receptors. 7-OH-MG exhibits higher potency at -opioid receptors than morphine, driving compulsive redosing, escalating tolerance, and physiological dependence. There is no accepted or approved medical use, and abrupt cessation in dependent individuals precipitates a classic opioid withdrawal syndrome.


Kratom Research, kratom
Kratom Involved in More Than 5,000 Overdose Deaths Since 2020 as Gas Station 7-OH Products Face Federal Scrutiny
11/17/2026

Death Counts and the Families Behind Them
The CDC figure counts overdose deaths involving kratom, and many also involved other substances. Even so, Justin Brower, a toxicologist at NMS Labs, told 60 Minutes that deaths attributed to kratom have risen roughly tenfold since 2014. He said he has seen dozens of deaths attributed to kratom alone, with no other drugs involved.
 


kratom, Kratom Research
Severe Kratom Withdrawal Induced by Oral Naltrexone: A Case Report and Call for Increased Awareness
10/25/2026

Background: Kratom is an illicit substance that has binding affinity to opioid receptors in high doses. Naltrexone is an opioid antagonist used for treatment of alcohol dependence; however, a 7- to 10-day washout period is required to avoid severe withdrawal in opioid users. There is currently no warning regarding concurrent kratom use in naltrexone prescribing information.


kratom, withdrawal, Kratom Research
Defining kratom: evidence-based policy guidelines for a rapidly evolving market
10/22/2026
kratom, Kratom Research
Kratom Is an Opioid
10/18/2026

Over the past century, new opioids have repeatedly been introduced with claims that they are fundamentally different from existing opioids and therefore safer or less addictive. Such claims have shaped clinical practice and regulatory policy, sometimes with profound negative public health consequences. One of the earliest examples followed Bayer’s introduction of heroin in the late 19th century, when company scientists claimed it was a safer, nonaddictive alternative to morphine.
Over the past decade, another opioid product has become widely available across the United States. Kratom, made from the leaves of a tree native to Southeast Asia, is now sold in the United States as dried powders, capsules, and concentrated liquid extracts and is widely available in gas stations and convenience stores. This growth in availability has been accompanied by a sharp rise in kratom-related harm. Between 2015 and 2025, US poison centers received 14,449 kratom exposure reports, rising from 258 in 2015 to a record 3434 in 2025—an increase of ~1200%


kratom, opioid, Kolodny, Kratom Research
Increases in Kratom-Related Reports to Poison Centers — National Poison Data System, United States, 2015–2025
09/06/2026
kratom, CDC, MMWR, Kratom Research
An exploratory study of the safety profile and neurocognitive function after single doses of mitragynine in humans
12/17/2024

Conclusion: The present study suggests that low doses (5-10 mg) of mitragynine may cause subjective feelings of stimulation and enhance attention, while the highest dose (40 mg) may cause inhibitory feelings of amnesia and distress. Mitragynine doses up to 40 mg were well tolerated in this group.


kratom, Kratom Research
Subscribe to Kratom Research